
1. AIDS. 2018 Nov 13;32(17):2605-2614. doi: 10.1097/QAD.0000000000002010.

CD4+ cell count recovery after combined antiretroviral therapy in the modern
combined antiretroviral therapy era.

Roul H(1), Mary-Krause M(1), Ghosn J(2), Delaugerre C(3), Pialoux G(4), Cuzin
L(5), Launay O(6), Lacombe JM(7), Menard A(8), De Truchis P(9), Delfraissy
JF(10), Weiss L(11), Costagliola D(1); FHDH-ANRS CO4.

Author information: 
(1)INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé
Publique.
(2)APHP, Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires
Paris Nord site Bichat-Claude Bernard, Université Paris Diderot, INSERM U 1137
IAME, PRES Sorbonne Paris-Cité.
(3)APHP, Service de virologie, Hôpital St Louis, Université Paris Diderot.
(4)APHP, Service des Maladies Infectieuses et Tropicales, Hôpital Tenon,
Université Paris Descartes, Sorbonne Paris-Cité, Paris.
(5)UMR1027, Université de Toulouse, UPS, Inserm, Toulouse, Service des Maladies
Infectieuses et Tropicales, CHU de la Martinique, Fort de France.
(6)APHP, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris-Cité.
(7)INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé
Publique, INSERM Transfert, Paris.
(8)Institut Hospitalo-Universitaire (IHU) - Méditerranée Infection, Marseille.
(9)Infectious Disease Departement, APHP, Hôpital Raymond Poincaré, Garches.
(10)APHP, Hôpital Bicêtre, Le Kremlin-Bicêtre.
(11)APHP, Hôpital Européen George Pompidou, Université Paris Descartes, Sorbonne 
Paris-Cité, Paris, France.

OBJECTIVE: To assess CD4 recovery after combined antiretroviral therapy (cART)
initiation with sustained virologic control.
DESIGN: Cohort study based on the French Hospital Database on HIV (FHDH-ANRS
CO4).
METHODS: We selected naive HIV-1-infected individuals initiating cART between
2006 and 2014 with CD4 cell counts less than 500 cells/μl who achieved virologic 
control, defined as two consecutive viral loads less than 50 copies/ml. We
estimated the cumulative incidence of CD4 recovery at least 500 cells/μl and
identified associated factors, considering 'virologic failure,' 'loss to
follow-up' and 'death' as competing events.
RESULTS: We analyzed 6050 individuals with a median follow-up of 14.2 months
since virologic control. The cumulative incidence for CD4 recovery after 6 years 
of virologic control reached 69.7%. The main factor associated with CD4 recovery 
was the CD4 count at treatment initiation [subdistribution hazard ratio (sHR)
9.64, 95% confidence interval (95% CI) 8.12-11.43 for CD4 cell counts between 350
and 500 cells/μl compared with CD4 cell counts <100 cells/μl). A higher CD4/CD8
ratio at initiation was also independently associated with a higher probability
of CD4 recovery [sHR 1.67; 95% CI 1.34-2.09] for a CD4/CD8 ratio ≥1.00 vs. <
0.30). Higher viral load at initiation was also associated with a higher
probability of CD4 recovery, whereas time to viral suppression was not.
CONCLUSION: After 6 years of sustained virologic control, a large majority of the
population achieved CD4 recovery. A higher CD4 cell count at initiation was a
strong predictor of CD4 recovery and, to a lesser extent, a higher CD4/CD8 ratio 
at initiation. These results confirm the necessity of early treatment.

DOI: 10.1097/QAD.0000000000002010 
PMID: 30289817  [Indexed for MEDLINE]

